Albemarle Corporation ALB remains committed to paying down debt and strengthening its balance sheet. The company paid down $1.3 billion of outstanding debt in March 2026, reducing annual interest expense by roughly $60 million. This followed the successful divestments of the controlling stake in Ketjen and its 50% interest in the Eurecat joint venture, which together generated $670 million in pre-tax proceeds.
ALB’s total long-term debt was roughly $1.88 billion at the end of the second quarter, down from $3.19 billion at the end of 2025. The company ended the quarter with a net debt-to-EBITDA leverage ratio of 0.5x compared with 1x at the end of the sequentially prior quarter. It has no major maturities due until late 2028.
At the end of the second quarter, ALB had liquidity of around $3.2 billion, including cash and cash equivalents of around $1.6 billion. Its deleveraging efforts are expected to continue to result in improved balance sheet and financial flexibility while reducing interest expenses. Factoring in the debt reduction actions completed in the first quarter of 2026, ALB sees interest and financing expense to be in the band of $120-$140 million for 2026.
Among its peers, Sociedad Quimica y Minera de Chile S.A. SQM exited the second quarter with long-term debt of around $4.79 billion. It had strong liquidity, with cash and cash equivalents of around $3.4 billion. Sociedad Quimica, in early December 2025, issued a hybrid bond for roughly $430 million to refinance debt and fund its investment plan.
ICL Group Ltd. ICL ended the second quarter with outstanding net debt of roughly $2.64 billion, up $375 million from the end of 2025. Including unutilized revolving credit facility and securitization, ICL Group had cash resources of $2.2 billion at the end of the quarter. ICL completed a private offering of $800 million senior notes due 2036 and plans to use part of the net proceeds from the offering for the repayment, in part or in full, of outstanding borrowings under its revolving credit facility maturing in April 2030, and to repay other debt.
ALB’s Price Performance, Valuation & Estimates
Albemarle has gained 15.3% over a year compared with the Zacks Chemical - Diversified industry’s decline of 3.3%.
ALB is currently trading at a forward price-to-sales ratio of 1.96, above the industry. It carries a Value Score of B.
The Zacks Consensus Estimate for ALB’s 2026 earnings implies a year-over-year rise of 1,541.8%. The EPS estimates for 2026 have been trending lower over the past 60 days.
ALB stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Albemarle Corporation (ALB): Free Stock Analysis Report
Sociedad Quimica y Minera S.A. (SQM): Free Stock Analysis Report
ICL Group Ltd. (ICL): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).